A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behcet's Disease
Phase of Trial: Phase III
Latest Information Update: 07 Jan 2016
At a glance
- Drugs Adalimumab (Primary)
- Indications Behcet's syndrome; Gastrointestinal disorders
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 07 Jun 2017 Biomarkers information updated
- 01 Jun 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Jul 2012 Planned end date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.